Phenothiazines as dual inhibitors of SARS-CoV-2 main protease and COVID-19 inflammation
- 1 October 2021
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Chemistry
- Vol. 99 (10), 801-811
- https://doi.org/10.1139/cjc-2021-0139
Abstract
COVID-19, caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) currently has no treatment for acute infection. The main protease (Mpro) of SARS-CoV-2 is an essential enzyme for viral replication and an attractive target for disease intervention. The phenothiazine moiety has demonstrated drug versatility for biological systems, including inhibition of butyrylcholinesterase, a property important in the cholinesterase anti-inflammatory cascade. Nineteen phenothiazine drugs were investigated using in silico modelling techniques to predict binding energies and inhibition constants (Ki values) with SARS-CoV-2 Mpro. Since most side-effects of phenothiazines are due to interactions with various neurotransmitter receptors and transporters, phenothiazines with few such interactions were also investigated. All compounds were found to bind to the active site of SARS-CoV-2 Mpro and showed Ki values ranging from 1.30 to 52.4 µM. Nine phenothiazines showed inhibition constants <10 µM. The compounds with limited interactions with neurotransmitter receptors and transporters showed micromolar (µM) Ki values. Docking results were compared with remdesivir and showed similar interactions with key residues Glu-166 and Gln-189 in the active site. This work has identified several phenothiazines with limited neurotransmitter receptor and transporter interactions and that may provide the dual action of inhibiting SARS-CoV-2 Mpro to prevent viral replication and promote the release of anti-inflammatory cytokines to curb viral-induced inflammation. These compounds are promising candidates for further investigation against SARS-CoV-2.Keywords
This publication has 56 references indexed in Scilit:
- Systems Biological Approach of Molecular Descriptors Connectivity: Optimal Descriptors for Oral Bioavailability PredictionPLOS ONE, 2012
- Inhibitors of Alphavirus Entry and Replication Identified with a Stable Chikungunya Replicon Cell Line and Virus-Based AssaysPLOS ONE, 2011
- Butyrylcholinesterase activity in multiple sclerosis neuropathologyChemico-Biological Interactions, 2010
- Quantitative Structure−Activity Relationship Modeling of Rat Acute Toxicity by Oral ExposureChemical Research in Toxicology, 2009
- Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathwayBrain, Behavior, and Immunity, 2009
- Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections?: Lack of efficacy of promazine on SARS-CoV replication in a mouse modelAntiviral Research, 2008
- Improving accuracy and efficiency of blind protein‐ligand docking by focusing on predicted binding sitesProteins, 2008
- Carbamates with Differential Mechanism of Inhibition Toward Acetylcholinesterase and ButyrylcholinesteraseJournal of Medicinal Chemistry, 2008
- Hepatitis C Virus Entry Depends on Clathrin-Mediated EndocytosisJournal of Virology, 2006
- Structure–activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivativesBioorganic & Medicinal Chemistry, 2005